CDSCO approves India’s first CAR-T cell therapy against certain blood cancers

ImmunoACT is an IIT Bombay incubated company-backed by drug maker Laurus Labs on Friday said it has received approval from Indian drug regulator the Central Drugs Standard Control Organization (CDSCO) for its CAR-T cell therapy NexCAR19 (actalycabtagene autoleucel), for the treatment of certain types of blood cancers.

NexCAR19 will be the first humanized CD19-targeted Chimeric Antigen Receptor T cell (CAR-T) therapy indigenously developed in India to be approved.

ImmunoACT didn’t reveal the pricing of the drug, but said it intends to make the NexCAR19 available to its partner hospitals as soon as possible.
ImmunoACT’s founder and CEO Rahul Purwar has in the past announced that its CAR-T cell therapy would be priced anywhere between Rs 30 lakh and Rs 40 lakh per patient, a lot cheaper compared to existing treatments. Each patient’s CAR-T cell therapy costs 3-4 crore (INR).

The multi-center phase I/II pivotal clinical trial, led by Dr Hasmukh Jain, was conducted with 60 patients of r/r B-cell lymphomas and leukemia.
The clinical data indicates 70% overall response rate (ORR). The safety profile in terms of cytokine release syndrome (CRS) and low-toxicity indicating a significant improvement over the other

commercially approved CD19-directed CAR-T cell therapies.

NexCAR19 is a collaborative effort across a decade, between the IIT-Bombay, and Tata Memorial Centre (TMC). Atharva Karulkar, Alka Dwivedi and the team led by Rahul Purwar, associate professor at IIT Bombay designed and developed the NexCAR19, which subsequently underwent integrative process development & manufacturing under cGMP at ImmunoACT.

Clinical investigations and translational studies were led by Dr Hasmukh Jain and Dr Gaurav Narula and their teams at Tata Memorial Hospitals.

“Now our patients in India and countries with limited resources will have access to this life-saving drug at an affordable cost,” said Purwar, Founder and CEO of ImmunoACT.

“In terms of technical achievement, this is comparable to the moon shot and it puts India on the elite list of select countries that have access to CAR-T therapy,” Purwar added.

Hyderabad-based drug maker Laurus Labs has been the early backer of ImmunoACT and has invested over $18 million to support ImmunoACT to scale its R&D and commercialization efforts.

Related Posts

  • Pharma
  • June 21, 2024
  • 48 views
Indian Pharmacopoeia Commission Flags ADR Linked To Meropenem

New Delhi: The Indian Pharmacopoeia Commission (IPC), through its recently issued drug safety alert for the month of May, has revealed that the carbapenem antibiotic Meropenem is linked with adverse drug…

  • Pharma
  • June 21, 2024
  • 52 views
Plan To Regulate Nutraceutical Industry Underway

NEW DELHI: India’s foods regulator is working on a draft regulation to clearly demarcate nutraceuticals and pharmaceutical drugs, to eliminate ambiguity and ensure that health supplements that are borderline pharma…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Indian Pharmacopoeia Commission Flags ADR Linked To Meropenem

Indian Pharmacopoeia Commission Flags ADR Linked To Meropenem

Plan To Regulate Nutraceutical Industry Underway

Plan To Regulate Nutraceutical Industry Underway

Ayush And Herbal Products Exports Grow Over 20% In April

Ayush And Herbal Products Exports Grow Over 20% In April

NMC Says No Antibiotics Before Diagnostic Tests

NMC Says No Antibiotics Before Diagnostic Tests

Health, Drug Control Officials To Monitor Sale Of Abortion Kits

Health, Drug Control Officials To Monitor Sale Of Abortion Kits

Punjab: 11-Month-Old Given Expired Vaccine At Amritsar’s Private Hospital

Punjab: 11-Month-Old Given Expired Vaccine At Amritsar’s Private Hospital